Q3 beat, strong Aerospace growth, $109.8B backlog, and dividend streak. Click here to read my most recent analysis.
AB-1009 is an investigational gene therapy that has not been approved by any regulatory authority, and its efficacy and safety have not been established or fully evaluated. For more information, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback